Synthesis and biological evaluation of novel urea-and guanidine-based derivatives for the treatment of obesity-related hepatic steatosis

11Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

Leptin, the product of the obese gene, is an adipocyte-secreted protein hormone playing a key role in the progression of obesity and hepatic steatosis. In this study, 28 novel (thio)urea and guanidine-based analogues have been synthesized and N-(1-(4-(3-(2-chloroethyl)ureido)benzyl)piperidin-4-yl)-3- (trifluoromethyl) benzamide (7i) was found to be a potent regulator of leptin expression in 3T3-L1 adipocytes. Treatment with 7i at a dose of 50 mg/kg/day for 35 days reduced the body weight and liver weight of diet-induced obesity mice by 13.5% and 18.4%, respectively, while also improving the serum levels of triglyceride, total cholesterol, leptin, adiponectin, LDL-c, HDL-c. Hematoxylin-eosin (H&E) and Oil Red O staining also confirmed that 7i ameliorated fat deposition in liver tissue and restricted the size of adipocytes in obesity-related fatty liver disease. © 2014 by the authors.

Cite

CITATION STYLE

APA

Liang, X., Pei, H., Ma, L., Ran, Y., Chen, J., Wang, G., & Chen, L. (2014). Synthesis and biological evaluation of novel urea-and guanidine-based derivatives for the treatment of obesity-related hepatic steatosis. Molecules, 19(5), 6163–6183. https://doi.org/10.3390/molecules19056163

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free